EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Evolving trends in acid suppression therapy among patients undergoing dual antiplatelet therapy: A Nationwide study in South Korea from 2018 to 2022

Yu Jeong Lee iD, Nam Kyung Je iD

British Journal of Clinical Pharmacology · 2025

DOI: 10.1111/bcp.16398 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Yu Jeong Lee und 1 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Pusan National University, Busan, Republic of Korea. Hauptthemen laut MEDLINE: Proton Pump Inhibitors, Histamine H2 Antagonists, Dual Anti-Platelet Therapy, Platelet Aggregation Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

We aimed to examine the recent trends in the use of acid suppression therapies, including proton pump inhibitors (PPIs), histamine‐2 receptor antagonists (H2RAs) and potassium‐competitive acid blockers (P‐CABs), in patients undergoing dual antiplatelet therapy (DAPT) as aspirin‐clopidogrel following coronary stent implantation in South Korea between 2018 and 2022.

Methods

This observational study analysed data from the Health Insurance Review and Assessment Service (HIRA) on patients who underwent coronary stent implantation and received aspirin‐clopidogrel DAPT. Patients who received acid suppression therapy for >60 days during DAPT were included in the analysis. Trends in the use of PPIs, H2RAs and P‐CABs were assessed at 6‐month intervals using the Cochran–Armitage trend test.

Results

Of the 128 121 patients studied who received DAPT, 61 731 (48.2%) were prescribed acid suppression therapy. The proportion of patients receiving concomitant acid suppressants with DAPT increased from 42.8% in 2018 to 53.8% in 2022. PPIs were the most commonly used therapies (78.9%), followed by H2RAs (14.6%) and P‐CABs (6.5%). PPI use peaked in 2020 and declined thereafter, whereas P‐CAB use steadily increased, surpassing that of H2RA by 2021.

Conclusions

The landscape of acid suppression therapy for patients undergoing DAPT has evolved with a growing preference for P‐CABs. This shift highlights the need for further research comparing the efficacy and safety of acid suppressants to guide clinical decision making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proton Pump InhibitorsHistamine H2 AntagonistsDual Anti-Platelet TherapyPlatelet Aggregation InhibitorsHumansRepublic of KoreaMaleFemaleMiddle AgedAspirinAgedClopidogrelPercutaneous Coronary InterventionStents

Stichwörter der Autor:innen

acid suppressionclopidogreldual antiplatelet therapyhistamine H2 antagonistspotassium‐competitive acid blockersproton pump inhibitors

Substanzen

Proton Pump InhibitorsAspirinHistamine H2 AntagonistsPlatelet Aggregation InhibitorsClopidogrel

Autor:innen und Institutionen

  • College of Pharmacy, Pusan National University, Busan, Republic of Korea.
  • Department of Pharmacy, Pusan National University Hospital, Busan, Republic of Korea.
  • Research Institute for Drug Development, Pusan National University, Busan, Republic of Korea.

ORCID-Profile: Yu Jeong Lee, Nam Kyung Je

Zitieren

APA

Lee, Y. J., & Je, N. K. (2025). Evolving trends in acid suppression therapy among patients undergoing dual antiplatelet therapy: A Nationwide study in South Korea from 2018 to 2022. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16398

Vancouver

Lee YJ, Je NK. Evolving trends in acid suppression therapy among patients undergoing dual antiplatelet therapy: A Nationwide study in South Korea from 2018 to 2022. British Journal of Clinical Pharmacology. 2025. doi:10.1111/bcp.16398

BibTeX
@article{Lee2025,
  author = {Lee, Yu Jeong and Je, Nam Kyung},
  title = {Evolving trends in acid suppression therapy among patients undergoing dual antiplatelet therapy: A Nationwide study in South Korea from 2018 to 2022},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1111/bcp.16398}
}
Kostenlos starten →